{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T19:25:39Z","timestamp":1743449139311,"version":"3.37.3"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004476","name":"Chinese Center for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004476","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Virological Methods"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.jviromet.2024.115102","type":"journal-article","created":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T01:02:21Z","timestamp":1734397341000},"page":"115102","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Development and implementation of a novel method for detecting hepatitis C virus resistance-associated substitutions to NS3, NS5A, and NS5B inhibitors in Linzhou, China"],"prefix":"10.1016","volume":"333","author":[{"given":"Cui","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yugang","family":"Nie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyu","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengjie","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqiu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenge","family":"Xing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maofeng","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongfu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jviromet.2024.115102_bib1","article-title":"The use of technology-based adherence monitoring in the treatment of hepatitis C virus","volume":"9","author":"Adje","year":"2022","journal-title":"Ther. Adv. Infect. Dis."},{"issue":"3","key":"10.1016\/j.jviromet.2024.115102_bib2","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.clinre.2019.07.015","article-title":"Baseline resistance associated substitutions in HCV genotype 1 infected cohort treated with Simeprevir, Daclatasvir and Sofosbuvir in Brazil","volume":"44","author":"Aguiar","year":"2020","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"issue":"2","key":"10.1016\/j.jviromet.2024.115102_bib3","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3390\/v11020148","article-title":"Geographic distribution of HCV-GT3 subtypes and naturally occurring resistance associated substitutions","volume":"11","author":"Bagaglio","year":"2019","journal-title":"Viruses"},{"issue":"3","key":"10.1016\/j.jviromet.2024.115102_bib4","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1128\/JVI.02294-12","article-title":"Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment","volume":"87","author":"Bartels","year":"2013","journal-title":"J. Virol."},{"issue":"5","key":"10.1016\/j.jviromet.2024.115102_bib5","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/hep4.1050","article-title":"Sequencing of hepatitis C virus for detection of resistance to direct-acting antiviral therapy: a systematic review","volume":"1","author":"Bartlett","year":"2017","journal-title":"Hepatol. Commun."},{"issue":"1","key":"10.1016\/j.jviromet.2024.115102_bib6","doi-asserted-by":"crossref","first-page":"8988","DOI":"10.1038\/s41598-018-26862-y","article-title":"Prevalence of Single and Multiple Natural NS3, NS5A and NS5B resistance-associated substitutions in hepatitis C virus genotypes 1-4 in Italy","volume":"8","author":"Bertoli","year":"2018","journal-title":"Sci. Rep."},{"issue":"11","key":"10.1016\/j.jviromet.2024.115102_bib7","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1093\/infdis\/jiy401","article-title":"Identification of a novel hepatitis C virus genotype from Punjab, India: expanding classification of Hepatitis C Virus into 8 genotypes","volume":"218","author":"Borgia","year":"2018","journal-title":"J. Infect. Dis."},{"issue":"07","key":"10.1016\/j.jviromet.2024.115102_bib8","first-page":"727","article-title":"Direct-acting antiviral agents in hepatitis C virus infection","volume":"31","author":"Cui","year":"2016","journal-title":"Clin. Focus"},{"key":"10.1016\/j.jviromet.2024.115102_bib9","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.coviro.2017.03.017","article-title":"Direct-acting antivirals: the endgame for hepatitis C?","volume":"24","author":"D'Ambrosio","year":"2017","journal-title":"Curr. Opin. Virol."},{"issue":"8","key":"10.1016\/j.jviromet.2024.115102_bib10","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1111\/liv.14797","article-title":"Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C","volume":"41","author":"Di Maio","year":"2021","journal-title":"Liver Int."},{"issue":"9","key":"10.1016\/j.jviromet.2024.115102_bib11","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.3390\/v13091832","article-title":"Genetic subtypes and natural resistance mutations in HCV genotype 4 infected saudi arabian patients","volume":"13","author":"Di Stefano","year":"2021","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.jviromet.2024.115102_bib12","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jhep.2022.08.016","article-title":"Long-term persistence of HCV resistance-associated substitutions after DAA treatment failure","volume":"78","author":"Dietz","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jviromet.2024.115102_bib13","doi-asserted-by":"crossref","unstructured":"European Association for Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015;63(1):199-236.\u00a0doi:10.1016\/j.jhep.2015.03.025.","DOI":"10.1016\/j.jhep.2015.03.025"},{"key":"10.1016\/j.jviromet.2024.115102_bib14","unstructured":"European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C: Final Update of the Series\u2730. J Hepatol; 73,5: 1170-1218.\u00a0doi:10.1016\/j.jhep.2020.08.0182020."},{"key":"10.1016\/j.jviromet.2024.115102_bib15","doi-asserted-by":"crossref","first-page":"W557","DOI":"10.1093\/nar\/gki352","article-title":"PHYML online--a web server for fast maximum likelihood-based phylogenetic inference","volume":"33","author":"Guindon","year":"2005","journal-title":"Nucleic Acids Res."},{"issue":"4","key":"10.1016\/j.jviromet.2024.115102_bib16","first-page":"637","article-title":"Worldwide prevalence, genotype distribution and management of hepatitis C","volume":"84","author":"Guntipalli","year":"2021","journal-title":"Acta Gastroenterol. Belg."},{"issue":"1","key":"10.1016\/j.jviromet.2024.115102_bib17","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jhep.2011.01.011","article-title":"Hepatitis C virus resistance to protease inhibitors","volume":"55","author":"Halfon","year":"2011","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.jviromet.2024.115102_bib18","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3390\/tropicalmed8020092","article-title":"Genotypes of hepatitis C virus and efficacy of direct-acting antiviral drugs among chronic hepatitis C patients in a tertiary care hospital","volume":"8","author":"Hawsawi","year":"2023","journal-title":"Trop. Med. Infect. Dis."},{"issue":"3","key":"10.1016\/j.jviromet.2024.115102_bib19","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz076","article-title":"Identification of 19 novel hepatitis C virus subtypes-further expanding HCV classification","volume":"6","author":"Hedskog","year":"2019","journal-title":"Open Forum Infect. Dis."},{"issue":"5","key":"10.1016\/j.jviromet.2024.115102_bib20","article-title":"Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals","volume":"4","author":"Howe","year":"2022","journal-title":"JHEP Rep."},{"issue":"9","key":"10.1016\/j.jviromet.2024.115102_bib21","first-page":"1378","article-title":"Research progress of HCV NS5A complex inhibitors","volume":"51","author":"Jiang","year":"2016","journal-title":"Acta Pharm. Sin."},{"issue":"5","key":"10.1016\/j.jviromet.2024.115102_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0155869","article-title":"Geno2pheno[HCV] - a web-based interpretation system to support hepatitis C treatment decisions in the era of direct-acting antiviral agents","volume":"11","author":"Kalaghatgi","year":"2016","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.jviromet.2024.115102_bib23","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01249-18","article-title":"Pooled resistance analysis in patients with hepatitis C virus genotype 1 to 6 infection treated with Glecaprevir-Pibrentasvir in phase 2 and 3 clinical trials","volume":"62","author":"Krishnan","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.jviromet.2024.115102_bib24","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/molbev\/msy096","article-title":"MEGA X: molecular evolutionary genetics analysis across computing platforms","volume":"35","author":"Kumar","year":"2018","journal-title":"Mol. Biol. Evol."},{"issue":"2","key":"10.1016\/j.jviromet.2024.115102_bib25","article-title":"Phylogenetic signature and prevalence of natural resistance-associated substitutions for hepatitis C virus genotypes 3a and 3b in southwestern China","volume":"8","author":"Liu","year":"2022","journal-title":"J. Virus Erad."},{"issue":"1","key":"10.1016\/j.jviromet.2024.115102_bib26","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3748\/wjg.v28.i1.96","article-title":"Risk of hepatocellular carcinoma after hepatitis C virus cure","volume":"28","author":"Luna-Cuadros","year":"2022","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.jviromet.2024.115102_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.meegid.2021.104949","article-title":"HCV resistance-associated substitutions following direct-acting antiviral therapy failure - Real-life data from Poland","volume":"93","author":"Parczewski","year":"2021","journal-title":"Infect. Genet Evol."},{"issue":"5","key":"10.1016\/j.jviromet.2024.115102_bib28","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1002\/hep.24262","article-title":"Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus","volume":"53","author":"Pawlotsky","year":"2011","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.jviromet.2024.115102_bib29","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/j.1365-2893.2012.01617.x","article-title":"Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents","volume":"19","author":"Poordad","year":"2012","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.jviromet.2024.115102_bib30","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.antiviral.2014.05.015","article-title":"Update on hepatitis C virus resistance to direct-acting antiviral agents. [111:154]","volume":"108","author":"Poveda","year":"2014","journal-title":"Antivir. Res."},{"issue":"5","key":"10.1016\/j.jviromet.2024.115102_bib31","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1097\/00042737-200105000-00007","article-title":"Outcome of liver disease in a large cohort of histologically proven chronic hepatitis C: influence of HCV genotype","volume":"13","author":"Roffi","year":"2001","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jviromet.2024.115102_bib32","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ijid.2020.03.061","article-title":"NS5A resistance - associated substitutions in chronic hepatitis C patients with direct acting antiviral treatment failure in Turkey","volume":"95","author":"Sayan","year":"2020","journal-title":"Int. J. Infect. Dis."},{"issue":"1","key":"10.1016\/j.jviromet.2024.115102_bib33","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.26744","article-title":"Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource","volume":"59","author":"Smith","year":"2014","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.jviromet.2024.115102_bib34","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.3390\/diagnostics12051054","article-title":"Distribution of primary resistance mutations in saint petersburg in patients with chronic hepatitis C","volume":"12","author":"Valutite","year":"2022","journal-title":"Diagnostics"},{"key":"10.1016\/j.jviromet.2024.115102_bib35","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jcv.2017.04.008","article-title":"A genotype independent, full-genome reverse-transcription protocol for HCV genotyping and resistance testing","volume":"91","author":"Walker","year":"2017","journal-title":"J. Clin. Virol."},{"issue":"2","key":"10.1016\/j.jviromet.2024.115102_bib36","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jhep.2017.03.014","article-title":"Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses","volume":"67","author":"Welzel","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jviromet.2024.115102_bib37","unstructured":"WHO. Global hepatitis report 2024.242.ISBN: 978-92-4-009167-2."},{"issue":"1","key":"10.1016\/j.jviromet.2024.115102_bib38","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12985-017-0710-z","article-title":"Hepatitis C Virus in mainland China with an emphasis on genotype and subtype distribution","volume":"14","author":"Zhang","year":"2017","journal-title":"Virol. J."}],"container-title":["Journal of Virological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166093424002271?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166093424002271?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T07:02:30Z","timestamp":1739343750000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166093424002271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":38,"alternative-id":["S0166093424002271"],"URL":"https:\/\/doi.org\/10.1016\/j.jviromet.2024.115102","relation":{},"ISSN":["0166-0934"],"issn-type":[{"type":"print","value":"0166-0934"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and implementation of a novel method for detecting hepatitis C virus resistance-associated substitutions to NS3, NS5A, and NS5B inhibitors in Linzhou, China","name":"articletitle","label":"Article Title"},{"value":"Journal of Virological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jviromet.2024.115102","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115102"}}